Menu
Menu
Colorectal cancer (CRC) is a critical health concern in Singapore and the Philippines. In Singapore, it’s the most common cancer overall and the second leading cause of cancer-related deaths.
Alarmingly, only about 40% of CRC cases are diagnosed at early stages, and just 38% of Singapore residents aged 50-74 undergo recommended CRC screening. Timely screening is crucial for early detection, which significantly improves treatment outcomes and survival rates. With early-stage CRC having over 90% 5-year survival rates compared to less than 10% for late-stage diagnoses, the importance of regular screening cannot be overstated.
ColonAiQ® offers a new, more accessible way to prioritize your health through early CRC detection.
Patient Preference: Most patients prefer blood tests over stool-based tests, potentially increasing screening compliance. (4)
Improved Early Detection: ColonAiQ® significantly increases detection rates for precancerous adenomas and early-stage CRC compared to existing molecular screening tests. (6)
ColonAiQ® is a cutting-edge, multi-locus blood-based assay that targets circulating tumor DNA methylation. This innovative technology offers unparalleled success in non-invasive early detection of both colorectal cancer (CRC) and advanced adenoma (AA). (6)
Stage distribution of CRC in Singapore (2018-2021): (2)
01. https://gco.iarc.who.int/media/globocan/factsheets/populations/702-singapore-fact-sheet.pdf
04. https://doi.org/10.1016/j.ctarc.2016.12.004
Liles, E. G., Coronado, G. D., Perrin, N., Harte, A. H., Nungesser, R., Quigley, N., Potter, N. T., Weiss, G., Koenig, T., & de Vos, T. (2017). Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: A randomized trial. Cancer Treatment and Research Communications, 10, 18-23. https://doi.org/10.1016/j.ctarc.2016.12.004
05. https://doi.org/10.1097/JS9.0000000000000260
Song, D., Wang, F., Ju, Y., He, Q., Sun, T., Deng, W., Ding, R., Zhang, C., Xu, Q., Qi, C., & Bao, J. (2023). Application and development of noninvasive biomarkers for colorectal cancer screening: a systematic review. International Journal of Surgery, 109(4), 925–935. https://doi.org/10.1097/JS9.0000000000000260
06. https://doi.org/10.1053/j.gastro.2021.08.054
Cai, G., Cai, M., Feng, Z., Liu, R., Liang, L., & Zhou, P. (2021). A Multilocus Blood-Based Assay Targeting Circulating Tumor DNA Methylation Enables Early Detection and Early Relapse Prediction of Colorectal Cancer. Gastroenterology, 161(6), 2053-2056.e2. https://doi.org/10.1053/j.gastro.2021.08.054
07. https://doi.org/10.1016/j.ctarc.2016.12.004
Liles, E. G., Coronado, G. D., Perrin, N., Harte, A. H., Nungesser, R., Quigley, N., Potter, N. T., Weiss, G., Koenig, T., & de Vos, T. (2017). Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: A randomized trial. Cancer Treatment and Research Communications, 10, 18-23. https://doi.org/10.1016/j.ctarc.2016.12.004
About Colonoscopy
https://www.gastrojournal.org/article/S0016-5085(21)03031-6/fulltext
Saver’s Med Pte Ltd is the exclusive distributor for Singlera’s ColonAiQ® in Singapore and the Philippines.
ColonAiQ is undergoing Health Sciences Authority (HSA) review for registration in Singapore and the Philippines.
Sign up for our waitlist to be among the first to be notified when ColonAiQ becomes available! Please leave your contact details.
